Definitive Contract 75F40124C00081
Award Date
9/16/24
Potential Completion Date
3/7/25
Potential Value
$1.1M
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
PSC Category
B529 - Special Studies/Analysis- Scientific Data
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10032, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price definitive contract awarded by the Food and Drug Administration (FDA) to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The contract, worth $243,473.00, is for a "Systematic Review of Neurodevelopmental Outcome in Vulnerable Pediatric Patient Populations" (BAAFDA-24-00123, referencing FY24C3DP2). This contract has no set-aside designation and is expected to be completed by March 7, 2025. As a...
This is a $1,721,851 firm fixed-price definitive contract awarded by the Food and Drug Administration (FDA) to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The contract, which does not have a set-aside designation, is for a study examining the effects of postnatal management approaches, including non-pharmacological and opioid replacement pharmacotherapy, as well as the timing and duration of gestational opioid exposure, on...
The U.S. Food and Drug Administration (FDA) awarded a time and materials delivery order contract worth $1,974,744.12 to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, to provide support for the FDA's Community Engagement and Development Initiative. This contract, which does not have a set-aside designation, will run through September 29, 2026. As a leading research institution, Columbia University has extensive expertise in biomedical...
The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, was awarded a $3,567,988.74 time and materials delivery order contract by the Food and Drug Administration (FDA) to provide support for the FDA's Community Engagement and Development Initiative. This contract, which does not have a set-aside designation, will run through March 7, 2025. As a leading research institution, Columbia University has extensive experience conducting biomedical...
The Department of Health and Human Services Food and Drug Administration awarded a $1,916,514.00 definitive contract to The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, to conduct research on neurodevelopmental outcomes in infants receiving opioid-replacement pharmacotherapy for neonatal opioid withdrawal syndrome (NOWS). The contract has a completion date of June 30, 2024 and does not utilize a set-aside designation. As part of this...
This is a federal contract award from the National Institute of Child Health and Human Development (NICHD), a civilian agency within the Department of Health and Human Services, to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The $94,591.05 delivery order is for biomedical research services and does not have a set-aside designation. The contract is a type of Indefinite Delivery Vehicle (IDV) that allows the CDC to continuously...
This is a firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Children's Research Institute, a pediatric research organization affiliated with Children's National Medical Center. The $176,933.97 contract is for "ADVANCING FETAL PHARMACOLOGY THROUGH REGULATORY SCIENCE" (PERINATAL HEALTH CENTER OF EXCELLENCE) and has a completion date of September 19, 2023. There is no set-aside designation for this award. Children's Research Institute has a strong...
This is a $1,904,355.00 definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA), a civilian government agency, to the Institute Of Quantitative Systems Pharmacology, a non-profit organization. The contract is for basic and applied research with two key objectives: (1) to test the hypothesis that variabilities in nanoparticle (NP) properties and tumor targets cause uncertainties in "FORMULA", and (2) to develop computational models to predict the...
This is a $2,814,105.00 firm fixed price definitive contract awarded by the U.S. Food and Drug Administration to the University of California, Los Angeles (UCLA) to provide research and development services to strengthen pharmacovigilance systems and adverse events reporting for maternal immunization safety in the Democratic Republic of Congo. The contract is a renewal of a prior year Broad Agency Announcement (BAA) solicitation for regulatory science and innovation, with no set-aside...
The U.S. Food and Drug Administration (FDA) awarded a $696,359 firm-fixed-price contract to Duke University's Office of Research Administration Division to conduct research and development activities in support of regulatory science and innovation. The contract, which does not have a set-aside designation, originated from a Broad Agency Announcement (BAA) that solicits advanced proposals across nine key areas to advance scientific knowledge in support of the FDA's mission to protect public...